Intec Pharma Ltd. is a tiny company in the space of pot stocks, doing clinical research involving cannabis. But one of their drugs failed a Stage III clinical trial. Intec’s stock got crushed and lost 81 percent of its value. Death of A Cannabis Stock Dream Intec has three drugs in its pipeline, including cannabis […]
The post Cannabis Stock Destroyed by 81% Decline on Clinical Trial Failure appeared first on CCN Markets
* First published on ccn.com
